WideMed Ltd. (TASE:WDMD) today announced successful results of a comparative study of its Morpheus Ox home sleep monitor on 135 patients with varying degrees of sleep apnea. The comparative in the US compared the device with devices at sleep clinics, and was intended to further support marketing of the device.
The study found good correlation between the results of the monitors at the clinics, which are the industry standard, and the Morpheus Ox. The Morpheus Ox achieved over 90% diagnostic accuracy based on the apneahypopnea index (AHI). Sleep clinics normally measure apnea via sensors attached to the patient. The Morpheus Ox monitors only the vascular photoplethysmography (PPG) signal using a proprietary algorithm for diagnosing sleep apnea.
Widemed president and CEO Anya Eldan said, "The company's successful extensive trial positions the Morpheus Ox system as a simple, easy-to-use, and accurate device for home sleep apnea diagnosis."
Widemed's share price rose 2.6% by midday to NIS 0.31, giving a market cap of NIS 6.5 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012